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ABSTRACT 
2′,3′-Dideoxynucleoside (ddNs) analogs are the most widely used anti-HIV drugs 
in the market. Even though these drugs display very potent activities, they have a 
number of limitations when are used as therapeutic agents. The primary problem 
associated with ddNs is significant toxicity, such as neuropathy and bone marrow 
suppression. Due to their hydrophilic nature, they have poor cellular uptake. Some of 
these nucleoside analogs develop resistance over a period of time. Furthermore, these 
analogs themselves are not pharmacologically active, and undergo three-step 
phosphorylation in order to become active. Of these steps, the first step is usually a 
slow and rate-limiting process.  
Herein, we report the synthesis and evaluation of 2′,3′-dideoxynucleoside 
conjugates with fatty acids with varying chain length and fatty acyl poly-L-arginine 
derivatives. The hypothesis of this project was that conjugating the nucleosides with 
fatty acids or fatty acyl poly-L-arginine derivatives will generate multifunctional 
agents with enhanced anti-HIV activity and cellular uptake, and less drug resistance 
development when compared to that of the parent nucleoside alone. Furthermore, the 
compounds will also have longer duration of action through sustained intracellular 
release of the parent nucleosides. The fatty acid conjugates of nucleosides could have 
higher uptake into the cells because of their enhanced lipophilicity. This dissertation 
will be revealed in two manuscripts. 
In the first Manuscript, the synthesis and anti-HIV activities of 5′-O-dicarboxylic 
fatty acyl monoester derivatives of 3'-azido-3'-deoxythymidine (zidovudine, AZT), 
2',3'-didehydro-2',3'-dideoxythymidine (stavudine, d4T), and 3'-fluoro-3'-
  
 
 
 
 
deoxythymidine (alovudine, FLT) are discussed. The compounds were synthesized to 
improve the lipophilicity and potentially the cellular delivery of parent polar 2′,3′-
dideoxynucleoside (ddN) analogs. Three different fatty acids with varying chain 
length of suberic acid (octanedioic acid), sebacic acid (decanedioic acid), and 
dodecanedioic acid were used for the conjugation with the nucleosides. Among all the 
compounds, 5′-O-suberate derivative of AZT (1, EC50 = 0.10 nM) exhibited the best 
anti-HIV profile when compared to other fatty acyl derivatives. The compound 
showed 80-fold higher anti-HIV activity than AZT without any significant toxicity 
(TC50  500 nM). This work was published in Tetrahedron Letters (2014, 
http://dx.doi.org/10.1016/j.tetlet.2014.02.001).    
In the second Manuscript, synthesis, anti-HIV activity, and preformulation tests 
of poly-L-arginine cell-penetrating peptides (CPPs) conjugated with fatty acyl 
derivatives of anti-HIV nucleosides, FLT, lamivudine (3TC) and emtricitabine (FTC) 
are discussed. All conjugates exhibited less anti-HIV activity when compared with the 
parent nucleoside analogues. For example, poly-L-arginine-fatty acyl derivative of 3-
fluoro-3-deoxythymidine, FLT-CO-(CH2)12-CO-(Arg)7, exhibited EC50 values of 2.9 
µM and 3.1 µM against X4 and R5 cell-free virus, respectively, while the FLT had 
EC50 values of 0.2 µM and 0.1 µM, suggesting the limited uptake or intracellular 
hydrolysis to the parent analogue. Further preformulation studies were done on the 
FLT-conjugate by determining the lipid solubility (partition coefficient) and solution 
state degradation. The compound was found to be stable in acidic and alkaline 
conditions. The partition coefficient (Log P) of FLT conjugate was found to be -0.34. 
The derivative was also evaluated in dissolution studies using four different hydrogels 
  
 
 
 
 
with and without a thermogelling polymer. Gel formulations of the compound were 
manufactured using non-ionic (HPC-SL) and anionic (Carbopol) polymers with and 
without the inclusion of a thermo-reversible gelling (Pluronic F-127) polymer. The 
compound was found to be unstable in the manufactured formulations as shown by 
HPLC profiles. This work has been submitted to a peer-reviewed journal. 
In summary, the studies provided more insights in designing new generation of 
anti-HIV nucleoside conjugates with fatty acids and poly-arginine CPPs. Overall, we 
have established a strategy for generation more potent nucleoside conjugates as shown 
in Manuscript I. Furthermore, the data indicated that addition of positively-charged 
poly-arginine to the nucleoside analogs is not beneficial in generating more potent 
anti-HIV conjugates as demonstrated in Manuscript II, possibly because of the 
presence of the positively charged viral glycoprotein gp120.  Further optimization of 
conjugated CPP-fatty acid-nucleoside conjugates is required to generate compounds 
with improved anti-HIV activity and optimized stability and formulation performance. 
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INTRODUCTION 
 
1. Acquired Immunodeficiency Syndrome (AIDS) 
 According to UNAIDS estimation, 2.6 million people were infected with 
Human Immunodeficiency Virus (HIV) infection and 1.7 million people died of 
Acquired Immunodeficiency Syndrome (AIDS) in 2011. This deadly syndrome is 
caused by infection by enveloped retrovirus HIV. HIV infects CD4
+
 T-lymphocytes, 
macrophages, monocytes and follicular dendritic cells, resulting in suppression of the 
host's immune system. Cell death, synctia formation, neuronal cell damage, dementia 
and myelopathy are the consequences of HIV infection (Staprans, 1997). A person 
infected with HIV shows illness trajectory characterized by clinical latency and an 
asymptomatic infection caused due to persistent viremia and humoral immune 
response (Brennan et al., 1997).  
 
2. Human Immunodeficiency Virus Structure 
HIV is 100-120 nm in diameter and belongs to the Lentivirus family. There are 
two types of HIV, HIV-1 and HIV-2. HIV-1 is the most predominant type of the virus. 
HIV-1 is capable to mutate and has M (10 different subtypes) and O subtypes (Quinn, 
1996). 
 HIV consists of central viral core and is surrounded by a lipid bilayer 
membrane (Figure 1). The membrane is interspersed with glycoprotein gp160 that is 
constituted from gp120 and gp41 glycoproteins. The gp120 trimer is non-covalently 
attached to the ectodomain gp41 transmembrane binding protein (Biscone et al., 
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2002). These glycoproteins are responsible for the viral binding to the host CD4
+
 T 
lymphocytes. The core viral capsule consists of p24, p7, and p9 core proteins and is 
surrounded by p17 protein. The capsid also includes two RNA strands and various 
viral enzymes like reverse transcriptase RNAse, polymerase, integrase, and protease, 
which are responsible for viral replication. The genes responsible for HIV-1 structural 
proteins and replication are gag, pol, env, vif, vpu, vpr, tat, rev and nef. 
 
Figure 1. Structure of HIV-1 
(Courtesy: http://www.stanford.edu/~rabriggs/hiv/hiv.html 9/15/12) 
 
3. HIV Receptors and Strains 
 Various HIV-1 isolates recognize two different kinds of co-receptors, CCR5 
and CXCR4. CCR5 co-receptors are expressed on macrophages and CD4 T cells and 
are called as R5 strains. CXCR4 co-receptors are expressed on CD4 T cells and are 
termed as X4 strains. CCR5 receptor plays a significant role in HIV transmission and 
R5 strains are the primary cause of HIV infection (O'Hara and Olson, 2002). 
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  During the viral binding process, the positively charged viral glycoprotein 
gp120 interacts with negatively charged CD4 receptor, and CCR5- and CXCR4 
coreceptors (Kajumo et al., 2000, Cheng-Mayer et al., 1997). These chemokine 
receptors are interspersed between the membranes and belong to two different classes 
of receptors, C-X-C (α-receptor) and C-C (β-receptor) (Deng et al., 1996). Therefore 
even HIV is divided into two types of strains, R5 and X4. R5 strains of virus uses 
CCR5 coreceptor and the X4 strains use the CXCR4 coreceptor to help attachment to 
the T lymphocytes.  
 
4. HIV-1 Life Cycle 
 The life cycle of the HIV-1 is divided into two phases: HIV-1 entry and 
development of infection resulting in viral assembly and budding. CD4
+
 host cell 
marker is required for the HIV-1 to undergo replication. The viral envelope 
glycoprotein (gp160) binds to the CD4 receptor and coreceptor. This energetically 
unfavorable process is driven by the conformational changes in the viral glycoprotein 
during the fusion process (Wyatt and Sodroski, 1998). The viral glycoprotein gp120 
helps in binding of the virus to the host CD4
+
 T lymphocytes. The fusion of the HIV-1 
envelope to the host cell membrane is aided by gp41 glycoprotein. CD4 receptor viral 
attachment induces conformational changes in gp41 enabling the insertion of N-
terminal hydrophobic peptide into the T-lymphocyte cell membrane. This is followed 
by rearrangement of the helical regions in ectodomain gp41 to form stable six-helix 
unit. The cofactors fusion and CC CKR5 are also essential for the viral entry. The 
virus penetrates into the cell and releases the viral content into the host cell cytoplasm 
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(Rowe, 1996). Hence, the viral receptors and the glycoprotein domain are major 
targets for the small molecule, entry, and/or fusion inhibitors. 
The HIV-1 needs to make proviral DNA from RNA in order to undergo 
replication. Reverse transcriptase (RT) catalyzes the formation of viral DNA and it 
consists of two enzymes: RNAse and polymerase enzymes. The RNA is converted to 
DNA in the presence of RNAse of RT. The DNA is duplicated to form double 
stranded DNA by polymerase enzyme activity of RT. The newly formed DNA then 
integrates with the host DNA in the nucleus in the presence of HIV integrase enzyme 
to form HIV-1 provirus (Figure 2). The proviral DNA undergoes transcription by 
cellular polymerases to RNA and upon translation basal amounts of Tat, Rev and Nef 
are produced (Jordan et al., 2001). 
 
gp41
gp120
Viral Protease
Viral Fusion
CD4 and 
Coreceptors
Reverse Transcriptase
Viral RNA
Proviral DNA
Host DNA Proviral DNA Polyprotein
Translation Protease
RNA
Viral Proteins
Post-translation 
modification
with NMT
Integrase
    Viral 
components
Host Cell
 
Figure 2. Life cycle of HIV (Agarwal, 2008). 
 
 Translation is activated when Tat binds to the TAR portion of the LTR and 
messenger RNAs are produced (Sierra et al., 2005). This mRNA moves out of the 
nucleus to facilitate formation of the polyproteins and enzymes, which are the 
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precursors of the capsid components (Figure 2). The protease enzyme splits the large 
polyproteins resulting in the formation of smaller glycoproteins and enzymes of the 
virus core. These polyproteins undergo myristoylation at N-terminal glycine residue 
with the aid of N-myristoyl transferase (NMT) enzyme (Figure 2). This process makes 
the polyproteins more lipophilic and allows them to move towards the cell membrane. 
The components will bud out together to form HIV-1 virions, which will undergo 
more changes and mature into infectious HIV-1 virus. 
 
5. Anti-Retroviral Drugs 
 The primary target for blocking HIV replication is the RT enzyme (Clercq, 
1992).  The main class of drugs acting against this enzyme is nucleoside reverse 
transcriptase enzyme inhibitors (NRTIs). Common anti-HIV NRTIs include 2′,3′-
dideoxynucleoside (ddN) analogs. Approved drugs by Food and Drug Administration 
(FDA) include 3'-azido-3'deoxythymidine (zidovudine, AZT), 2',3'-dideoxy-3'-
thiacytidine (lamivudine, 3TC), 2',3'-didehydro-2',3'-dideoxythymidine (stavudine, 
d4T), 2',3'-dideoxy-5-fluoro-3'-thiacytidine (emtricitabine, FTC), 2',3'-dideoxycytidine 
(zalcitabine, ddC), and 3'-fluoro-3'-deoxythymidine (FLT).  
 The mechanism of NRTIs is inhibiting of viral RNA conversion to proviral 
DNA. NRTIs interrupt RNA-DNA transcription in the virus-infected cells. These 
analogs themselves are not pharmacologically active, and undergo three-step 
phosphorylation to become active. The anti-HIV NRTIs are phosphorylated 
intracellularly to mono-, di- and triphosphates by cellular kinases.  
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 This triphosphate form acts as reverse transcriptase substrate, competes with 
the naturally occurring nucleosides, and is incorporated into the growing proviral 
DNA chain (Tan et al., 1999). NRTIs do not have a hydroxyl group at 3′ position of 
the ribose (Lee et al., 2001). The incorporation of nucleoside analogs in DNA causes 
chain termination and inhibition of elongation, and thereby inhibits viral replication. 
 Current antiretroviral nucleosides do not eliminate the virus thoroughly and 
complete restoration of the immune functions does not occur. There are several 
complications associated with antiretroviral therapy like poor adherence, limited 
access, low therapeutic index, and short duration of action due to the nucleoside short 
half-life, dependence on cellular kinases for activation and development of mutation in 
HIV-1 that causes viral resistance to these drugs (Parang et al., 2000). The primary 
problem associated with ddNs is significant toxicity such as neuropathy and bone 
marrow suppression.  
Furthermore, NRTIs have limited cellular uptake and bioavailability owing to 
their hydrophilic nature. To overcome their limited cellular uptake, various prodrugs, 
ddN analogs have been synthesized with increased lipophilicity (Parang et al., 1998, 
1997, Agarwal, 2011). 
 The so-called highly active antiretroviral therapy (HAART) includes at least 
two different classes of antiretroviral drugs. HAART has reduced plasma viremia to 
unnoticeable levels and increased CD4
+
 T cell count. This therapeutic strategy has 
many limitations that include serious side effects, development of viral resistance, and 
pharmacokinetic interactions (Duran et al., 2001).  
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 It has been demonstrated that even under HAART therapy there is persistent 
viral replication undergoing in the lymph nodes and lymphoid tissues (Hamer, 2004). 
This is due to low levels of the drug and presence of residual virus in these tissues. 
Lymphoid and central nervous system (CNS) tissues serve as viral reservoirs. Thus, 
sufficient drug exposure and delivery to these tissues are critical regardless of their 
target of action. In order to maximize the antiviral potential of a particular therapy and 
to prevent recurring infections, development of novel, safe, less toxic, and more 
effective broad-spectrum anti-HIV drugs targeting different stages of the viral life 
cycle. Furthermore, drug delivery approaches that reduce the residual viral load are 
still needed to help prevent the progression of the HIV infection. 
There are no candidate vaccines in the pipeline that can induce sterilizing 
immunity and protect against infection with HIV.  Therefore, there is an urgent need 
to develop additional safe and effective treatment and preventative strategies. One of 
those strategies has become known as microbicides, topically applied agents to the 
vagina or rectum that prevent or reduce transmission of sexually transmitted 
organisms, in particular HIV/AIDS. 
The development of a female controlled prevention method in the form of a 
topical microbicide to protect a woman from contracting HIV remains a high priority. 
Despite the successful outcome of the Caprisa 004 trial (Abdool Karaim et al., 2010), 
the most advanced product available (Tenofovir gel) is still only partially effective in 
preventing the transmission of HIV. For this reason, it is critical to continue the 
development of a pipeline of potent and novel inhibitors that have the potential to be 
effective as microbicides. In addition, it is critical to define optimized delivery 
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methods for these products that will place the microbicide at the right place, at the 
right time, and at the right concentration to prevent the initial infection events in the 
vagina and/or rectum. 
Current development in the microbicide field has become highly focused on 
anti-HIV compounds approved for therapeutic use.  These include the NRT inhibitor 
tenofovir, the non-nucleoside RT inhibitor dapivirine, and the CCR5 antagonist 
maraviroc, as well as various combinations of these drugs (Abdool Karim et al, 2010, 
Mertenskoetter et al., 2011). Since complete transmission inhibition has not yet been 
achieved with any microbicide product, it becomes even more important to continue to 
exploit the potential of other non-FDA approved antiretroviral compounds with 
varying mechanisms of action. 
 
6. Objectives of Research 
 The conjugation of nucleosides with fatty acyl and polyarginine-fatty acyl 
residues are investigated to generate anti-HIV agents and to circumvent some of the 
problems associated with using parent anti-HIV nucleosides. This combination may 
result in development of anti-HIV microbicides having enhanced efficacy, longer 
duration of action by sustained intracellular release of active substrates at adequate 
concentrations, and/or higher uptake into the infected cells. The combination of these 
residues with NRTIs may reduce the toxicity associated with nucleosides. 
Furthermore, development of viral resistance to two active drugs would occur at lower 
rate than to either compound alone. 
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Manuscript I 
 The first Manuscript discusses the synthesis and biological evaluation of fatty 
acyl derivatives of antiretroviral nucleosides that include AZT, FLT and d4T. The 
fatty acyl conjugates of nucleosides are proposed to act against HIV by inhibiting the 
viral enzymes, RT and NMT, by nucleosides and fatty acid analogs, respectively. 
These bifunctional agents are expected to improve the cellular uptake by enhancing 
the lipophilicity of the conjugates, to reduce the cytotoxicity of the parent nucleosides, 
and to show higher genetic barrier to resistance through dual mechanism of antiviral 
action. 
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Figure 3. Proposed mechanism of action of 5′-O-fatty acyl derivatives of nucleosides. 
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 The main purpose of this project is to develop bifunctional anti-HIV agents by 
covalently attaching nucleoside reverse transcriptase inhibitors to fatty acids with 
varying chain length (Figure 4). The fatty acid attachment will increase the 
lipophilicity and thereby improve the cellular uptake of these bifunctional conjugates.  
These specifically designed bifunctional agents provide a novel approach to design 
highly efficacious anti-HIV microbicides. Nucleosides and fatty acid act as reverse 
transcriptase inhibitors and viral NMT inhibitors, respectively (Fig 3). This 
bifunctional strategy yields antiviral agents with enhanced efficacy, longer duration of 
action provided by sustained intracellular drug release and higher cellular uptake.  
 
Figure 4. Design of 5′-O-(fatty acyl) ester nucleoside derivatives 
 
Manuscript II 
 The second manuscript discusses the synthesis and biological evaluation of 
polyarginine-fatty-acyl derivatives of anti-HIV nucleosides, FLT, FTC and 3TC. The 
main objective of the conjugation of poly-L-arginine residues to fatty acylated 
nucleosides was to improve the efficacy and delivery of the agents in HIV-1-infected 
cells. Once it enters the cells, the conjugate undergoes intracellular hydrolysis to 
release the three components, polypeptide, fatty acid and the anti-HIV nucleoside. The 
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fatty acyl and nucleoside derivatives exert their action against reverse transcriptase 
(RT) and N-myristoyl transferase (NMT) viral enzymes. The fatty acyl moiety 
increases the lipophilicity and thereby improves the cellular uptake of the conjugates. 
The poly-L-arginine component is involved not only as a carrier but also acts as a cell-
penetrating peptide due to the presence of many positively charged guanidinium 
groups.  
 
 Another objective of designing both classes of compounds in Manuscripts I 
and II is to develop anti-HIV microbicides for vaginal application. The conjugation of 
fatty acyl or poly-L-arginine-fatty acyl residue to the nucleoside may result in 
microbicides with enhanced efficacy and longer duration of action. Among 
compounds in class II, FLT conjugate was selected and its stability under different 
conditions was evaluated. Preformulation studies were conducted to determine the 
solution state degradation and partition coefficient of the selected conjugate. The 
dissolution studies were conducted by manufacturing four different hydrogels with or 
without polymer.  These studies evaluate the stability and formulation performance of 
the compound in the vaginal hydrogels intended to act as microbicidal agents. 
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1.1. Abstract 
A number of 5′-O-dicarboxylic fatty acyl monoester derivatives of 3'-azido-3'-
deoxythymidine (zidovudine, AZT), 2',3'-didehydro-2',3'-dideoxythymidine 
(stavudine, d4T), and 3'-fluoro-3'-deoxythymidine (alovudine, FLT) were synthesized 
to improve the lipophilicity and potentially the cellular delivery of parent polar 2′,3′-
dideoxynucleoside (ddN) analogs. The compounds were evaluated for their anti-HIV 
activity. Three different fatty acids with varying chain length of suberic acid 
(octanedioic acid), sebacic acid (decanedioic acid), and dodecanedioic acid were used 
for the conjugation with the nucleosides. The compounds were evaluated for anti-HIV 
activity and cytotoxicity. All dicarboxylic ester conjugates of nucleosides exhibited 
significantly higher anti-HIV activity than that of the corresponding parent nucleoside 
analogs. Among all the tested conjugates, 5′-O-suberate derivative of AZT (EC50 = 
0.10 nM) was found to be the most potent compound and showed 80-fold higher anti-
HIV activity than AZT without any significant toxicity (TC50  500 nM).   
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1.2. Introduction 
 Highly Active Antiretroviral Therapy (HAART) for the treatment for human 
immunodeficiency virus (HIV) includes using different classes of anti-HIV agents, 
including nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) along with protease inhibitors (Agarwal, 2008). 
2′,3′-Dideoxynucleoside (ddN) analogs are similar to naturally occurring nucleosides, 
but they cannot be used for the synthesis of new DNA as they lack the 3-hydroxyl 
group. These agents act as nucleoside reverse transcriptase inhibitors (NRTIs) and 
thereby cause DNA chain termination. NRTIs have shown severe adverse effects, 
mitochondrial toxicity, and resistance to multi-drug resistant HIV (Otto, 2004; Tan et 
al., 1999; Lewis et al., 2006; Lund et al., 2007). Furthermore, nucleoside analogs are 
polar in nature and have limited cellular uptake. Novel anti-HIV agents are urgently 
needed with a better safety and resistance profile for the prevention and treatment of 
HIV infection. 
 Prevention of HIV transmission to women is essential to avoid transmission of 
the virus to the newborn. Nevirapine, a non-nucleoside reverse transcriptase inhibitor 
is known to lower the risk of HIV-1 transmission in breastfeeding population by 
nearly 50% during the first 14-16 weeks of life (Laura et al., 1999). Currently there are 
no vaccines developed to provide protection against HIV. Thus, it is a necessity to 
develop additional safe, effective treatment and preventative strategies.  
Microbicidal agents are agents which are topically applied to the vagina or rectum to 
prevent the transmission of sexually transmitted organisms. Microbicides which are 
focused on the prevention of HIV transmission target vaginal, cervical or rectal 
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mucosa and may act via several mechanisms, such as the non-specific direct 
inactivation of the virus (Balzarini and Damme, 2007). Currently known microbicides 
in development, such as UC-781 (thiocarboxanilide), TMC-120 (dapivirine), MIV-
150, and tenofovir, act specifically via a single mechanism of the inhibition of reverse 
transcriptase enzyme (Mauck and Doncel, 2001). Developing new anti-HIV 
microbicides that are multifunctional anti-HIV agents is urgently needed to reduce the 
incidence of drug resistance. Furthermore, the lipophilic microbicides could bind 
tightly or irreversibly to the HIV envelope, leading to inactivation of cell-free, or cell-
associated virus or both resulting in a significant decrease in virus transmission.  
 Furthermore, there have been several reports on lipids acting as antiviral and 
antibacterial agents (Thormar et al., 1987). The medium length chain saturated fatty 
acids are one of those agents that inhibit enveloped viruses like HIV and herpes 
simplex virus type 1 (HSV-1) (Kristmundsdottir, 1999). Microbicidal hydrogels of 
these fatty acids have been developed and evaluated, and they possibly act by 
disrupting the viral lipid membrane (Kristmundsdottir, 1999). HIV-1 replication is 
inhibited by heteroatom substituted myristic acid analogs without showing any 
significant cellular toxicity. Myristoylated HIV proteins include PR160gag-pol, 
Pr55gag, p17gag, and p27nef. Myristic acid analogs inhibit the N-myristoyl 
transferase (NMT) that catalyzes the N-myristoylation of HIV proteins (Langner et al., 
1992). 2-Methoxydodecanoic acid, 4-oxatetradecanoic acid, and 12-
thioethyldodecanoic acid have shown to reduce HIV-1 replication in acutely infected 
T-lymphocytes (Parang et al., 1997). For example, 12-thioethyldodecanoic acid 
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derivative was moderately active (EC50 = 9.4 M) against HIV-infected T4 
lymphocytes. 
Several studies have demonstrated the use of lipids as active intravaginal 
microbicide agents to protect against various sexually transmitted infections (STIs) 
(Thormar et al., 1987; Langner et al., 1992; Kristmundsdottir, 1999). When lipid-
associated drugs are administered subcutaneously, they are usually distributed 
throughout the lymphoid system with improved stability, and the drug can be 
delivered at higher concentrations (Kinman et al., 2003). This is a major advantage 
since HIV is hidden in the lymphatic system not accessible by many commercially 
available polar anti-HIV nucleosides.  
 Thus, designing lipophilic anti-HIV nucleosides for developing anti-HIV 
agents or anti-HIV microbicides is a subject of major interest. The most predominant 
approach to this strategy is the esterification strategy between nucleosides and fatty 
acids. The in vitro chemical stability of ester conjugates helps to produce formulations 
with adequate shelf lives. The esters also act as the substrates for esterase enzyme and, 
therefore, are labile in vivo (Sriram et al., 2004). The 5′-O-hydroxyl esterification of 
the anti-HIV nucleosides also provides a viable approach to increase cellular delivery 
of polar nucleosides. We have previously shown that fatty acyl monocarboxylic ester 
derivatives of 3'-azido-3'-deoxythymidine (zidovudine, AZT) (Parang et al., Antiviral. 
Chem. Chemother. 1998, Parang et al., 2000), 3'-fluoro-3'-deoxythymidine (alvudine, 
FLT) (Parang et al., Nucleosides & Nucleotides 1998), (-)-2',3'-dideoxy-3'-thiacytidine 
(lamivudine, 3TC) (Agarwal et al., 2012), 5-fluoro-(-)-2',3'-dideoxy-3'-thiacytidine 
(emtricitabine, FTC) (Agarwal et al., 2013), and 2',3'-didehydro-2',3'-
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dideoxythymidine (stavudine, d4T) (Agarwal et al, 2011) with enhanced anti-HIV 
activity against CXC4-tropic, CCR5-tropic  cell-associated, and/or multi-drug resistant 
strains of virus. The fatty acid substitution with FTC and 3TC showed a significant 
increase in their cellular uptake in comparison to their parent nucleosides (Agarwal et 
al, 2012, 2013).   
 Herein, we report the synthesis and evaluation of novel 5-O-fatty acyl ester 
derivatives of AZT, d4T, and FLT using dicarboxylic fatty acids. As shown before for 
other conjugates, fatty acids were expected to improve the lipophilicty of polar 
nucleoside analogs and cellular uptake and to generate lipophilic agents with higher 
anti-HIV activity. Dicarboxylic acids instead of monocarboxylic fatty acids were 
selected to generate more amphipathic property in the structure of conjugates due to 
the presence of additional polar free carboxylic acid. 
 
1.3. Materials and Methods 
1.3.1. Materials 
 FLT and AZT were purchased from Euro Asia Tran Continental (Bombay, 
India). Stavudine (d4T) was purchased from Kemprotec (Middlesbrough, U.K.). 
HBTU, HOBt, 1,6-octanedioic acid, 1,8-decanedioic acid, and 1,12-dodecanedioic 
acid were purchased from Sigma Aldrich Chemical Co. Solvents and all the other 
reagents were purchased from Fisher scientific. Phenomenex®Gemini 10 µm ODS 
reversed-phase column (2.1 × 25 cm) was used along with Hitachi HPLC system for 
the purification of the synthesized final products. The HPLC method was a gradient 
system at a constant flow rate of 18 ml/min (Table 1.1). 
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 Hitachi analytical HPLC system was used to determine the purity of the 
compounds. Analytical C18 column (Grace Allsphere ODS 2-3 µ, 150 × 4.6 mm) with 
water:acetonitrile (30:70 v/v) system at a constant flow rate of 1 ml/min was used to 
determine the purity of the final products. The compounds showed UV detection at 
265 nm. A Bruker NMR spectrometer (400 MHz) was used for characterization, and 
the chemical shifts were reported in parts per millions (ppm). The chemical structures 
of the final products were confirmed by high-resolution PE Biosystems Mariner API 
time-of-flight electrospray mass spectrometry. 
 
1.3.2. Chemistry 
1.3.2.1. General method for the synthesis of 5′-O-(fatty Acyl) esters of FLT, d4T 
and AZT (17). Nucleoside (AZT, FLT, or d4T, 0.58 mmol), fatty acid 
(HOOC(CH2)nCOOH, (suberic acid (octanedioic acid, n = 8), sebacic acid 
(decanedioic, n = 10), and dodecanedioic acid (n = 12), 3.8 mmol), 2-(1H-
benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU, 720 mg, 
1.9 mmol), 1-hydroxybenzotriazole (HOBt (255 mg, 1.2 mmol), 
diisopropylcarbodiimide (DIC, 200 µL, 1.15 mmol), and N,N-diisopropylethylamine 
(DIPEA, 2 mL, 15 mmol) were dissolved in dry N,N-dimethylformamide (DMF, 10 
mL). The reaction mixture was stirred at room temperature overnight. The completion 
of reaction was confirmed by TLC. The mixture was concentrated and dried under 
vacuum. The residues were purified with reversed phase HPLC using C18 column and 
water/acetonitrile as solvents (Table 1.1). The purity of the final products (>95%) was 
confirmed by using a Hitachi analytical HPLC system on a C18 column using 
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water:acetonitrile (30:70 v/v) at a constant flow rate of 1 mL/min with UV detection at 
265 nm. 
 
Table 1.1. HPLC method used for purification of the final products (1-7). 
 
Time 
(min) 
Water 
Concentration 
A (%) 
Acetonitrile 
Concentration 
B (%) 
Flow rate 
(mL/min) 
0.00 100.0 0.0 1.0 
1.00 100.0 0.0 18.0 
45.0 40.0 60.0 18.0 
50.0 0.0 100.0 18.0 
55.0 0.0 100.0 18.0 
60.0 100.0 0.0 18.0 
60.1 100.0 0.0 1.0 
 
 
8-[(3′-Azido-2′,3′-dideoxythymidinyl)-5′-yl]octandioate (1). Yield (100 mg, 20%); 
1
H NMR (400 MHz, CD3OD, δ ppm): 7.40 (s, 1H, H-6), 6.10 (t, J = 6.0 Hz, 1H, H-1′), 
4.20-4.40 (m, 3H, H-3′, H-5′, H-5′′), 4.00-4.15 (m, 1H, H-4′), 2.90-3.00 (m, 2H, -
CH2COOH), 2.80-2.90 (m, 2H, -CH2COO), 2.20-250 (m, 4H, H-2′ and H-2′′, 
CH2CH2COOH and -CH2CH2COO), 1.85 (s, 3H, 5-CH3), 1.50-1.80 (m, 2H, -
CH2CH2CH2COOH), 1.22-1.40 (m, 2H, -CH2CH2CH2COO); HR-MS (ESI-TOF) 
(m/z): C18H25N5O7: calcd, 423.1754; found, 424.2143 [M + H]
+
. 
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10-[(3′-Azido-2′,3′-dideoxythymidinyl)-5′-yl]decandioate (2). Yield (120 mg, 24%); 
1
H NMR (400 MHz, CD3OD, δ ppm): 7.47 (s, 1H, H-6), 6.14 (t, J = 6.4 Hz, 1H, H-1′), 
4.32-4.42 (m, 3H, H-3′, H-5′), 4.29 (dd, J = 4.0 and 12.0 Hz, 1H, H-5′′), 4.03 (dd, J = 
4.8 and 9.2 Hz, 1H, H-4′), 2.34-2.50 (m, 4H, -CH2COOH, H-2′ and H-2′′), 2.27 (t, J = 
7.4 Hz, 2H, -CH2COO), 1.89 (s, 3H, 5-CH3), 1.50-1.70 (m, 4H, CH2CH2COOH, 
CH2CH2COO), 1.25-1.40 (br m, 8H, methylene protons); 
13
C NMR (CD3OD, 100 
MHz, δ ppm): 177.56 (COOH), 174.75 (COOAZT), 166.15 (C-4 C=O), 152.06 (C-2 
C=O), 137.73 (C-6), 111.76 (C-5), 86.54 (C-1′), 83.03 (C-4′), 64.51 (C-5′), 62.17 (C-
3′), 37.77 (C-2′), 34.87 (CH2COO), 30.21, 31.18, 30.12, 30.06, 26.00, 25.94, 25.89 
(methylene carbons), 12.64 (5-CH3); HR-MS (ESI-TOF) (m/z): C20H29N5O7: calcd, 
451.2067; found, 452.2699 [M + H]
+
. 
 
12-[(3′-Azido-2′,3′-dideoxythymidinyl)-5′-yl]dodecandioate (3). Yield (115 mg, 
23%); 
1
H NMR (400 MHz, CD3OD, δ ppm): 7.48 (s, 1H, H-6), 6.14 (t, J = 6.3 Hz, 1H, 
H-1′), 4.20-4.50 (m, 3H, H-3′, H-5′ and H-5′′), 3.98-4.20 (m, 1H, H-4′), 3.55-3.75 (m, 
4H, -CH2COOH, -CH2COO), 2.20-2.50 (m, 4H, CH2CH2COOH, H-2′ and H-2′′), 1.89 
(s, 3H, 5-CH3), 1.48-1.65 (m, 2H, CH2CH2COO), 1.25-1.35 (br m, 12H, methylene 
protons); 
13
C NMR (CD3OD, 100 MHz, δ ppm): 177.66 (COOH), 174.78 (COOAZT), 
166.22 (C-4 C=O), 152.10 (C-2 C=O), 137.78 (C-6), 111.79 (C-5), 86.61 (C-1′), 83.11 
(C-4′), 64.55 (C-5′), 62.22 (C-3′), 37.77 (C-2′), 34.98, 34.94, 34.84, 30.72, 30.64, 
30.62, 30.42, 30.28, 30.23, 30.20, 26.12, 26.05, 25.99 (methylene carbons), 12.66 (5-
CH3); HR-MS (ESI-TOF) (m/z): C22H33N5O7: calcd, 479.2380; found, 480.2448 [M + 
H]
+
.  
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10-[5′-O-(3′-Fluoro-2′,3′-dideoxythymidinyl)]decandioate (4). Yield (200 mg, 
40%); 
1
H NMR (400 MHz, CD3CN, δ ppm): 7.44 (s, 1H, H-6), 6.18 (dd, J = 5.6 and 
8.9 Hz, 1H, H-1′), 5.30 (dd, J = 5.0 and 53.2 Hz, 1H, H-3′), 4.47 (dt, J = 3.5 and 26.7 
Hz, 1H, H-4′), 4.36 (dd, J = 4.4 and 12.1 Hz, 1H, H-5′), 4.24 (dd, J = 3.5 and 12.1 Hz, 
1H, H-5′′), 2.50-2.70 (m, 1H, H-2′′), 2.20-2.40 (m, 5H, CH2COOH, CH2COO, H-2′), 
1.87 (s, 3H, 5-CH3), 1.50-1.65 (m, 4H, CH2CH2COO), 1.20-1.40 (br m, 8H, 
methylene protons); 
13
C NMR (CD3CN, 100 MHz, δ ppm): 177.45 (COOH), 174.88 
(COOFLT), 165.82 (C-4 C=O), 151.73 (C-2 C=O), 136.81 (C-6), 111.77 (C-5), 95.00 
(J = 175.9 Hz, C-3′), 86.01 (C-1′), 83.24 (J = 26.4 Hz, C-4′), 64.29 (J = 11.0 Hz, C-
5′), 38.37 (J = 20.9 Hz, C-2′), 34.54, 34.51 (CH2COO), 29.54, 29.49, 29.46, 29.43, 
29.39, 25.38, 25.31 (methylene carbons), 12.55 (5-CH3); HR-MS (ESI-TOF) (m/z): 
C20H29FN2O7: calcd, 428.1959; found, 427.197 [M - H]
+
. 
 
12-[5′-O-(3′-Fluoro-2′,3′-dideoxythymidinyl)]dodecandioate (5). Yield (200 mg, 
40%); 
1
H NMR (400 MHz, CD3OD, δ ppm): 7.36 (s, 1H, H-6), 6.28 (dd, J = 5.5 and 
8.7 Hz, 1H, H-1′), 5.20 (dd, J = 4.4 and 53.4 Hz, 1H, H-3′), 4.30-4.50 (m, 2H, H-4′, H-
5′), 4.18-4.30 (m, 1H, H-5′′), 2.53-2.70 (m, 1H, H-2′′), 2.20-2.40 (m, 5H, CH2COOH, 
CH2COO, H-2′), 1.88 (s, 3H, 5-CH3), 1.50-1.70 (m, 4H, CH2CH2COO), 1.15-1.40 (br 
m, 12H, methylene protons); 
13
C NMR (CD3OD, 100 MHz, δ ppm): 177.33 (COOH), 
174.16 (COOFLT), 165.42 (C-4 C=O), 151.44 (C-2 C=O), 136.06 (C-6), 111.82 (C-
5), 94.23 (J = 178.9 Hz, C-3′), 86.00 (C-1′), 83.17 (J = 26.5 Hz, C-4′), 64.03 (J = 10.6 
Hz, C-5′), 38.55 (J = 21.1 Hz, C-2′), 34.66, 34.63 (CH2COO), 30.08, 30.00, 29.97, 
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29.85, 29.78, 29.70, 29.64, 25.52, 25.40 (methylene carbons), 12.78 (5-CH3); HR-MS 
(ESI-TOF) (m/z): C22H33FN2O7: calcd, 456.2272; found, 495.1764 [M + K]
+
. 
 
10-[(2',3'-Didehydro-2',3'-dideoxythymidine)-5′-yl]decandioate (6). Yield (220 
mg, 44%); 
1
H NMR (400 MHz, CD3OD, δ ppm): 7.41 (s, 1H, H-6), 6.85-6.95 (m, 1H, 
H-1'), 6.39 (d, J = 5.8 Hz, 1H, H-3'), 5.99 (d, J = 5.9 Hz, 1H, H-2'), 5.00-5.10 (m, 1H, 
H-4'), 4.39 (dd, J = 4.2 and 12.4 Hz, 1H, H-5''), 4.21 (dd, J = 2.9 and 12.4 Hz, 1H, H-
5'), 2.24-2.42 (m, 4H, CH2COOH and CH2COO), 1.88 (s, 3H, 5-CH3), 1.50-1.68 (m, 
4H, CH2CH2COOH and CH2CH2COO), 1.16-1.44 (br m, 8H, methylene protons); 
13
C 
NMR (CDCl3, 100 MHz, δ ppm): 177.62 (COOH), 174.87 (COO), 166.33 (C-4 C=O), 
152.70 (C-2 C=O), 137.83 (C-6), 134.87 (C-3'), 127.83 (C-2'), 111.51 (C-5), 91.36 (C-
1'), 85.83 (C-4'), 65.77 (C-5'), 34.92, 34.78 (CH2COOH and CH2COO), 30.24, 30.22, 
30.15, 30.07, 26.05, 25.98, 25.92 (methylene carbons), 12.72 (CH3); HR-MS (ESI-
TOF) (m/z): C20H28N2O7, calcd, 408.1897; found, 407.186 [M - H]
+
.  
 
12-[(2',3'-Didehydro-2',3'-dideoxythymidine)-5′-yl]dodecandioate (7). Yield (180 
mg, 36%); 
1
H NMR (400 MHz, CD3OD, δ ppm): 7.30 (s, 1H, H-6), 6.90-6.95 (m, 1H, 
H-1'), 6.33 (d, J = 6.0 Hz, 1H, H-3'), 5.76 (d, J = 5.8 Hz, 1H, H-2'), 5.00-5.10 (m, 1H, 
H-4'), 4.38 (dd, J = 4.0 and 12.4 Hz, 1H, H-5''), 4.21 (dd, J = 2.9 and 12.4 Hz, 1H, H-
5'), 2.28 (dt, J = 7.5 and 22.2 Hz, 4H, CH2COOH and CH2COO), 1.88 (s, 3H, 5-CH3), 
1.50-1.68 (m, 4H, CH2CH2COOH and CH2CH2CO), 1.16-1.34 (br m, 12H, methylene 
protons); 
13
C NMR (CDCl3, 100 MHz, δ ppm): 177.35 (COOH), 174.44 (COO), 
165.61 (C-4 C=O), 152.06 (C-2 C=O), 136.7 6 (C-6), 134.21 (C-3'), 127.52 (C-2'), 
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111.44 (C-5), 90.58 (C-1'), 85.06 (C-4'), 65.27 (C-5'), 34.67 (CH2COOH and 
CH2COO), 30.11, 30.03, 30.00, 29.87, 29.82, 29.73, 29.66, 25.55, 25.39 (methylene 
carbons), 12.82 (CH3); HR-MS (ESI-TOF) (m/z): C22H32N2O7, calcd, 436.2210; 
found, 435.216 [M - H]
+
. 
 
1.3.3. Anti-HIV Assays 
Anti-HIV-1 Evaluation in PMBC Assay. PBMC based anti-HIV assays were 
performed as previously described (Watson et al., 2008). Briefly, PHA-stimulated 
PBMCs cultured in the presence of IL-2 were suspended at 1 × 10
6
 cells/mL and were 
added to a 96-well round-bottom plate. Serially diluted test materials were added to 
the plate in triplicate followed by the appropriate pre-titered strain of HIV. The culture 
was incubated for 7 days at 37 °C/5% CO2. Following the incubation, supernatants 
were collected for analysis of virus replication by supernatant RT activity and cells 
analyzed for viability by XTT dye reduction. AZT was used as an internal assay 
standard. All the assays were carried out in triplicate. 
 
1.4. Results and Discussion 
1.4.1. Chemistry 
 The synthesis of seven mono-substituted 5′-O-(fatty acyl)esters of nucleosides 
is shown in Figure 1.1.  Three nucleosides, FLT, AZT, and d4T, and three different 
dicarboxylic fatty acids were used for esterification. The conjugates were synthesized 
by reacting nucleosides and dicarboxylic fatty acids in N,N-dimethylformamide 
(DMF) in the presence of 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
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hexafluorophosphate (HBTU), 1-hydroxybenzotriazole (HOBt) and 
diisopropylcarbodiimide (DIC) as coupling reagents and N,N-diisopropylethylamine 
(DIPEA) as a base. The reaction mixtures were stirred at room temperature overnight. 
The final products were purified by HPLC on C-18 column using water and 
acetonitrile as the solvent system in order to achieve more than 95% purity. The 
chemical structures of the final products were characterized by nuclear magnetic 
resonance spectrometry (
1
H NMR and 
13
C NMR), and were confirmed by a high–
resolution time-of-flight electrospray mass spectrometer. 
 
Figure 1.1. Synthesis of 5′–mono-substituted fatty acyl ester nucleoside conjugates of 
FLT, AZT, and d4T (1-6). 
 
1.4.2. Biological Evaluation 
 All the synthesized conjugates were evaluated for their inhibitory activity of 
HIV–1 (subtype B, US/92/727) replication in human peripheral blood mononuclear 
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(PBMC) cells (Watson et. al., 2008) Table 1.2 illustrates the anti-HIV-1 activity 
(EC50) and cytotoxicity (TC50) of the nucleoside ester conjugates compared with their 
corresponding parent nucleosides. No cytotoxicity was observed up to the highest 
tested concentration for both the parent nucleosides and the synthesized conjugates 
(TC50  500 nM) (1-7).  
 The AZT conjugates (1-3, EC50 = 0.1-0.3 nM) exhibited consistently higher 
anti-HIV activity than that of AZT (EC50 = 8.0 nM). For example, octandioate 
(suberate) ester derivative of AZT (1, EC50 = 0.1 nM) showed 80 times higher anti-
HIV activity than the parent nucleoside. AZT conjugates having longer chain fatty 
acids also showed enhancement in anti-HIV activity than AZT while the ratio of 
improvement was less than that of compound 1. The decandioate ester of AZT (2, 
EC50 = 0.31 nM) was 26-fold more potent than that of AZT. The activity of 
dodecandioate ester of AZT (3) was 24 times higher when compared to AZT. Among 
the AZT conjugates, AZT-suberate conjugate (1) showed the highest anti-HIV 
activity. These data suggest that conjugation of AZT with dicarboxylic acids 
significantly enhances the anti-HIV activity with higher potency seen in conjugates 
with shorter chain length. 
 Similarly, dicarboxylic ester conjugates of d4T (6 and 7, EC50 = 1.98-18.3 nM) 
showed better anti-HIV activity from that of d4T (EC50 = 90 nM) in the PBMC assay 
against HIV–1US/92/727. The decanedioate ester of d4T (6, EC50 = 1.98 nM) exhibited 
45 times more anti-HIV activity than d4T. The dodecandioate ester of d4T (7, EC50 = 
18.3 nM) showed 5 times higher anti-HIV activity when compared to that of its parent 
nucleoside. These results indicate that the anti-HIV activity of the carboxylic esters of 
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anti-HIV  nucleoside depends on the chain length of the carboxylic acid, and shorter 
length dicarboxylate monoester conjugates are more potent. 
 A similar trend was observed for FLT ester conjugates compared to the parent 
nucleoside. Amongst all the FLT conjugates (EC50 = 0.25-0.26 nM), the decanedioate 
ester of FLT (4, EC50 = 0.26 nM) and dodecanedioate ester of FLT (5, EC50 = 0.25 
nM) showed 8-fold increase in anti-HIV activity when compared to FLT (EC50 = 2 
nM), but the difference in anti-HIV activity between the two conjugates was not 
significant. 
 There was a significant increase in the therapeutic index of AZT and FLT 
derivatives when compared to that of the respective parent nucleosides. The increased 
therapeutic index indicates synergistic effect of conjugation of dicarboxylic acids with 
ddNs. Among all the synthesized dicarboxylic acid ester derivatives of AZT, FLT, and 
d4T, the decandioate monoester conjugate of AZT (1) showed the highest anti-HIV 
activity. 
 This study indicates that NRTIs when in conjugation with long chain 
dicarboxylic acids exhibit higher anti-HIV activity possibly due to the improved 
lipophilicity thereby increasing the cellular uptake of NRTIs. As shown by calculated 
partition coefficient values (Table 1), the ester conjugates were more lipophilic that 
their parent analogs. We have shown previously for other fatty acyl derivatives of 
nucleosides that
 
the highly lipophilic conjugates could have higher cellular uptake 
contributing to their improved anti-HIV activity (Agarwal 2012, 2013). However, for 
dicarboxylic monoester conjugates, an appropriate lipophilicty is required for an 
optimal anti-HIV activity since highly lipophilic conjugates with longer chain length 
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were less potent than those with shorter chain length. We have previously shown 
higher cellular uptake and the intracellular hydrolysis of several fatty acyl ester 
derivatives of 3TC, d4T, and FTC (Agarwal et al, 2011, 2012, 2013). Similarly, it is 
expected that when the conjugate esters enter the cells, they undergo intracellular 
hydrolysis by esterases and release the anti-HIV nucleosides and fatty acids targeting 
different stages of the HIV life cycle possibly contributing to enhanced anti-HIV 
activity. Nucleoside and fatty acid analogs are known to target the reverse 
transcriptase and the NMT enzymes. More mechanistic studies are required to 
determine the exact mechanism of activity of the ester conjugates of the nucleosides.  
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Table 1.2. Anti-HIV activity of dicarboxylic acid ester conjugates of nucleoside 
conjugates (1-7). 
Com
pd. 
Chemical Name 
PBMC/HIV-1US/92/727  
EC50 
(nM)
a
 
TC50 
(nM)
b
 
TI
c
 
Log 
P
d
 
      
AZT 3'-azido-2',3'-dideoxythymidine 8.00 >1000 >125 -0.24
e
 
FLT 3'-fluoro-2',3'-deoxythymidine 2.00 >500 >250 -0.41 
d4T 
2',3'-didehydro-2',3'-
dideoxythymidine 
90.0 >500 >5.6 
-0.34 
      
1 
8-[(3′-azido-2′,3′-
dideoxythymidinyl)-5′-
yl]octandioate 
0.10 >500 >5000 
1.97
e
 
2 
10-[(3′-azido-2′,3′-
dideoxythymidinyl)-5′-
yl]decandioate 
0.31 >500 >1613 
3.03
e
 
3 
12-[(3′-azido-2′,3′-
dideoxythymidinyl)-5′-
yl]dodecandioate 
0.33 >500 >1516 
4.09
e
 
      
4 
10-[5′-O-(3′-fluoro-2′,3′-
dideoxythymidinyl)]decandioate 
0.26 >500 >1923 
1.99 
5 
12-[5′-O-(3′-fluoro-2′,3′-
dideoxythymidinyl)]dodecandioate 
0.25 >500 >2000 
2.83 
      
6 
10-[(2',3'-didehydro-2',3'-
dideoxythymidine)-5′-
yl]decandioate 
1.98 >500 >253 
2.06 
7 
12-[(2',3'-didehydro-2',3'-
dideoxythymidine)-5′-
yl]dodecandioate 
18.30 >500 >27 
2.90 
      
 
a
EC50 (50% effective concentration), 
b
TC50 (50% toxic concentration), 
c
Therapeutic 
index(TC50/EC50); 
d
Calculated Partition coefficient by ChemDraw Ultra 12.0; 
e
CLogP 
calculated by ChemDraw Ultra 12.0.
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1.5. Conclusions 
 Several lipophilic 5′-O-fatty acyl dicarboxylic monoester derivatives of the 
nucleoside reverse transcriptase inhibitors, AZT, FLT, and d4T were synthesized and 
evaluated for their anti-HIV activity. The fatty acid substitution at the 5′-O-position 
enhanced the lipophilicity of the anti-HIV nucleoside analogs. All conjugates 
exhibited higher anti-HIV activity when compared to their parent nucleosides. The 
improved viral inhibition by the AZT, d4T, and FLT fatty acyl derivatives versus the 
parent nucleoside is presumably due to the enhanced cellular uptake of the lipophilic 
conjugates. These conjugates have the potential to be used as potent anti-HIV agents 
and/or lipophilic anti-HIV microbicides after further optimization.  
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2.1. Abstract 
The objective of this study was to design, synthesize, and evaluate poly-L-arginine 
cell-penetrating peptides (CPPs) conjugated with fatty acyl derivatives of anti-HIV 
nucleosides. Three conjugates of alovudine (FLT), lamivudine (3TC) and 
emtricitabine (FTC) were synthesized through solid-phase synthesis from the 
conjugation of Wang-resin bound fatty acyl poly-L-arginine with FLT and N4-
protected 3TC and FTC, followed by cleavage and deprotection. The final products 
were purified by HPLC and characterized by 
1
H-NMR, 
13
C- NMR, and mass 
spectroscopy, and were evaluated for cytotoxicity and anti-HIV activity. All 
conjugates exhibited less anti-HIV activity when compared with the parent nucleoside 
analogues. For example, poly-L-arginine-fatty acyl derivative of 3-fluoro-3-
deoxythymidine, FLT-CO-(CH2)12-CO-(Arg)7, exhibited EC50 values of 2.9 µM and 
3.1 µM against X4 and R5 cell-free virus, respectively, while the FLT had EC50 values 
of 0.2 µM and 0.1 µM, suggesting the limited uptake or intracellular hydrolysis to the 
parent analogue. The FLT-conjugate was selected for further preformulation studies 
by determination of solution state degradation and lipid solubility (partition 
coefficient). The compound was found to be stable in neutral and oxidative conditions, 
moderately stable in heated conditions, and unstable in acidic and alkaline conditions. 
The FLT conjugate was hydrophilic as the partition coefficient (Log P) was found to 
be -0.34. The stability of the compound was evaluated using HPLC. The derivative 
was evaluated in dissolution studies using four different hydrogels gels with and 
without a thermogelling polymer. Gel formulations of the compound were 
manufactured using non-ionic (HPC-SL) and anionic (Carbopol) polymers with and 
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without the inclusion of a thermo-reversible gelling (Pluronic F-127) polymer. The 
compound was found to be unstable in the manufactured formulations as shown by 
HPLC profiles. These data suggest that the conjugation of poly-Arg to fatty acyl 
derivatives of anti-HIV nucleosides do not generate conjugates with improved anti-
HIV activity versus the parent nucleosides and they lack adequate stability. Further 
investigation is required in order to generate nucleoside-fatty acid-CPP conjugates 
with improved anti-HIV activity and optimized dissolution and stability in 
formulations.  
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2.2. Introduction 
 According to UNAIDS estimation, 35.3 million people are living with 
Acquired Immunodeficiency Syndrome (AIDS) in 2013 (www.unaids.org). High 
Activity Antiretroviral Therapy (HAART) involves the use of a minimum of three 
types of antiretroviral drugs including protease inhibitors, non-nucleoside reverse 
transcriptase inhibitors, and nucleoside reverse transcriptase inhibitors. HAART has 
increased the lifespan of HIV-infected patients and has converted this terminal illness 
into a chronic and manageable disease (Clercq, 2007). Although the FDA approved 
anti-HIV nucleosides zidovudine (AZT), lamivudine (3TC), and emtricitabine (FTC) 
have reduced the mortality rate in patients, their use is still complicated because of 
toxicity, chronic intake, development of resistant virus, and incomplete elimination of 
the viral reservoirs. These anti-HIV nucleosides have also limited cellular uptake due 
to their hydrophilic nature. Upon intracellular uptake, they need to undergo three 
phosphorylation steps in order to become active nucleoside triphosphate analogues 
(Clercq, 2007). Thus, novel drug delivery systems are urgently needed in order to 
generate nucleoside conjugates with better anti-HIV profile, such as higher cellular 
uptake and anti-HIV activity. 
 The primary hypothesis of this work was to design conjugates of anti-HIV 
nucleosides conjugated with fatty acids and cell penetrating polyArg peptides. Herein, 
we designed polyArg-fatty acyl derivatives of anti-HIV nucleosides with the 
expectation to overcome their limited cellular uptake. The objective was to design 
multifunctional anti-HIV drug conjugates where:  
1. Nucleosides act as reverse transcriptase inhibitors (NRTIs); 
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2. Long chain fatty acyl component acts as N-myristoyl transferase (NMT) 
inhibitor and also improves the cellular uptake; and 
3. The Poly-L-arginine component plays a crucial role as a cell-penetrating 
peptide. 
 
Long chain Carboxylic acids as NMT Inhibitors: Long chain carboxylic acids are 
known to inhibit NMT, which is responsible for the myristoylation of various HIV 
proteins, such as P17 capsid protein, Pr55
gag
, Pr160
gag-pol
, and p27
nef
 in the virus 
infected host cells (Langner et al., 1992). Myristoylation of viral proteins allows the 
viral protein components to become more hydrophobic (Farazi et al., 2001). Certain 
heteroatom-containing myristic acid analogues, such as 12-thioethyldodecanoic acid, 
4-oxatetradecanoic acid and 2-methoxydodecanoic acid derivatives, inhibit HIV-1 
replication in acutely infected T-lymphocytes (Bryant et al., 1993; Takamune et al., 
2002). 12-Thioethyldodecanoic acid was found to be moderately active against HIV 
infected T4 lymphocytes with an EC50 value of 9.4 µM (Parang et al., 1997).  
 Various 5-O-fatty acyl derivatives of nucleoside reverse transcriptase 
inhibitors (3'-azido-3'-deoxythymidine (zidovudine, AZT), 3'-fluoro-3'-
deoxythymidine (alovudine, FLT), (-)-2',3'-dideoxy-3'-thiacytidine (lamivudine, 3TC), 
5-fluoro-(-)-2',3'-dideoxy-3'-thiacytidine (emtricitabine, FTC), 2',3'-didehydro-2',3'-
dideoxythymidine (stavudine, d4T)) were found to have enhanced anti-HIV activity 
profiles as compared to their parent nucleosides against X4, R5 strains, cell-
associated, and/or multi-drug resistant virus, presumably due to increased cellular 
uptake caused by their high lipophilic profile (Parang et al., 1996, 1997, 1998, 2000; 
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Agarwal et al, 2011, 2012, 2013). These ester conjugates were shown to act as 
bifunctional agents through intracellular hydrolysis by esterases to release nucleoside 
reverse transcriptase inhibitors, and the fatty acids.  
 
Poly-L-Arginine as a Cell Penetrating Peptide: An important subclass of these 
molecular transporters are CPPs, which contain guanidinium-rich transporters (GRTs). 
The positively charged guanidinium groups on the arginine side chains are responsible 
for its penetrating ability through interaction with the phospholipid bilayer. The 
development of theses polyarginine transporter molecules was inspired by the lead 
HIV-1 transcription transactivator protein (Tat) made up of repeated arginine and 
lysine residues (Wender et al., 2008). This transporter is highly polar, readily soluble 
in water, and unlike other polar drugs travels across the lipid bilayer membrane 
(Wender et al., 2008). Studies have shown that peptides with 6-20 arginine residues 
pass through the membrane showing rapid uptake across the membrane and into the 
nucleus without any signs of acute toxicity (Wender et al., 2008). Molecular 
transporters when attached to poorly bioavailable drugs could enable them to pass 
through the biological membrane as shown previously (Rothbard et al, 2000). 
 Anti-HIV microbicides are topically applied agents that prevent or reduce 
transmission of infectious disease, particularly HIV/AIDS (Lederman et al., 2006). 
One of the major issues of anti-HIV drug delivery is to obtain selective uptake of the 
drug at the targeted site, and one of the strategies for selectivity is local or direct 
administration of the drug. GRTs such as polyarginine peptide penetrate both the 
epidermal and dermal layers of the skin upon topical application (Wender et al., 2008). 
 45 
 
Thus, the poly-L-arginine peptide was expected to act in an anti-HIV microbicidal 
vaginal application. The compounds were expected to have potential to be used for the 
development of anti-HIV microbicides. 
Polyarginine-Fatty Acyl Conjugates. Myristoylated polyarginine peptide (MPAP) has 
a noninvasive and non-disruptive mode of transportation across the blood brain barrier 
(BBB) wherein the myristoyl group promotes membrane association and the positively 
charged polyArg undergoes electrostatic interactions with the negative charges of the 
BBB cell membranes (Pham et al., 2005).
 
MPAP was attached to an optically 
detectable dye, and in vivo imaging showed accumulation in the mouse brain 
especially in the neurons (Pham et al., 2005). Thus, CPP-fatty acyl conjugates of 
nucleoside could have also application for targeting HIV infected brain cells.
 
 Various peptide-derived HIV entry/fusion inhibitors of CXCR4, a chemokine 
co-receptor found on CD4
+
 T lymphocytes, have been reported to mimic the HIV-1 
Tat basic domain designed to target the transactivator response element (TAR) RNA 
of HIV-1 (Borkow et al., 2003). For example, the nona-arginine peptide binds TAR 
RNA with high affinity in vitro (Hamy et al., 1997). Thus, we hypothesized that when 
poly-L-arginine is attached to fatty acylated nucleosides, it could also act as possible 
CXCR4 HIV entry inhibitor. Upon cellular entry, the peptide linker is cleaved by 
protease, thereby allowing the fatty acylated nucleoside to localize in the nucleus and 
other cellular components. 
 
Herein, we report the design, synthesis, and biological activities of three poly-
L-arginine linked poly-Arg 1,12-dodecanedicarboxylate derivatives of anti-HIV 
nucleosides (FLT, 3TC, and FTC (Figure 2.1) and their application as multifunctional 
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anti-HIV agents. It was expected that
 
the conjugation of nucleosides to the poly-L-
arginine-fatty acyl residue could result in the development of anti-HIV agents or 
microbicides with enhanced efficacy, longer duration of action by sustained 
intracellular release of active substrates at adequate concentrations, and/or higher 
uptake into infected cells. Furthermore, the development of viral resistance to two or 
more active drugs might be expected to occur at a lower rate than to either compound 
alone.  
Nucleoside Analogue Fatty acid
Cell-Penetrating 
Poly-Arg Peptide
R7
1,12-Dodecanedicarboxylic acid 
 
Figure 2.1. Poly-L-arginine linked fatty acylated nucleosides. 
 
2.3. Materials and Methods 
2.3.1. Materials 
 Nucleosides (1-3) were purchased from Euro Asia Trans Continental (Bombay, 
India) for the nucleoside ester conjugate synthesis. [2-(1H-benzotriazol-1-yl)-1,1,3,3-
tetramethyluronium-hexafluorophosphate] (HBTU), N,N-diisopropylethylamine 
(DIPEA), and 1,12-dodecanedicarboxylic acid were bought from Sigma Aldrich 
Chemical Co. Solvents and all other reagents were purchased from Fisher Scientific. 
The products were purified using a Phenomenex-Gemini C18 column (10 µm, 250 × 
21.2 mm) with Hitachi HPLC system using a gradient system at a constant flow rate of 
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10 ml/min (Table 2.1). The purity of the final products was confirmed by using a 
Hitachi analytical HPLC system on a C18 column using a gradient system 
(water:acetonitrile 30:70 v/v) at a constant flow rate of 1 ml/min with UV detection at 
220 nm and 265 nm. The chemical structures of the final products were determined by 
nuclear magnetic resonance spectrometry (
1
H NMR and 
13
C NMR) on a Bruker NMR 
spectrometer (400 MHz) and confirmed by a SELDI-TOF mass spectrometer on a 
Ciphergen protein chip instrument using α-cyano-4-hydroxycinnamic acid as a matrix. 
 
Table 2.1. HPLC method used for purification of the final compounds. 
Time 
(min) 
Water 
Concentration 
A (%) 
Acetonitrile 
Concentration 
B (%) 
Flow rate 
(mL/min) 
0.00 100.0 0.0 1.0 
1.00 
5.0 
100.0 
90.0 
0.0 
10.0 
10.0 
10.0 
25.0 70.0 30.0 10.0 
35.0 60.0 40.0 10.0 
60.0 0.0 100.0 10.0 
65.0 0.0 100.0 10.0 
70.0 100.0 0.0 1.0 
 
 
2.3.2. Chemistry 
 
Synthesis of Polyarginine (11). The peptide synthesis was carried out in Bio-Rad 
polypropylene columns by shaking and mixing using a Glass Col small tube rotator or 
on a PS3 automated peptide synthesizer (Rainin Instrument Co., Inc.) at room 
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temperature unless otherwise stated. Fmoc-Arg(Pbf)-Wang resin (10, 1.1 mmole, 2.97 
g, 0.37 mmole/g) was placed in manual peptide synthesis container (250 mL) 
equipped with a three way stopper. Resin was swelled in N,N-dimethylformamide 
(DMF, 150 mL) with constant N2 bubbling for 30 min (2 times). The Fmoc group was 
removed from the resin in the presence of piperidine (20% v/v in DMF, 2 × 50 mL) 
for 15 min. The resin was washed with DMF (5 × 50 mL). Fmoc-Arg(Pbf)-OH (3 
equiv, 3.3 mmol, 2.14 g) and HBTU (3 equiv, 1.25 g, 3.3 mmol) were added to the 
reaction vessel, followed by the addition of DMF (25 mL) and DIPEA (6 equiv, 6.6 
mmol, 1.15 mL) (Scheme 2) and bubbled with N2 for 2.5 h. The resin was washed 
with DMF (5 × 25 mL) to remove unreacted starting materials, impurity, and reagents. 
The deprotection and coupling cycles were repeated five more times to add a total of 7 
arginine residues on the resin. N-Terminal Fmoc was deprotected by using piperidine 
(20 % v/v in DMF) to afford resin 11.  Resin 11 was washed with DMF (5 × 100 mL). 
The structure of 11 was confirmed by cleaving a small amount of the resin in the 
presence of reagent R (TFA/thioanisole/1,2-ethanedithiol/anisole, 90:5:3:2 v/v/v/v, 2 
mL) for 4 h. The crude peptide was precipitated in the presence of cold diethyl ether 
(Et2O, 150 mL), and separated and washed by centrifugation (3 × 15 mL) at 4000 rpm 
for 5 min. The crude peptide was dissolved in water (0.1%, TFA). The molecular 
weight of poly-L-arginine (R7) was confirmed by a SELDI-TOF mass spectrometer on 
a Ciphergen protein chip instrument. MS (SELDI-TOF) (m/z): C42H86N28O8, calcd, 
1111.3; found, 1111.1 [M]
+
. 
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Synthesis of Polyarginine 1,12-Dodecanedicarboxylate (12). 1,2-
Dodecanedicarboxylic acid (1.43 g, 5.5 mmol), HBTU (2.09 g, 5.5 mmol), and 1-
hydroxy-7-azabenzotriazole (HOAt, 0.74 g, 5.5 mmol) were added to the reaction 
vessel containing polyargine resin 11 in anhydrous DMF (200 mL), followed by the 
addition of DIPEA (8.1 mmol, 1.42 mL) and N,N'-diisopropylcarbodiimide (DIC, 9.0 
mmol, 1.4 mL) (Scheme 2). The peptidtyl resin was bubbled with N2 for 7 h and then 
washed with DMF (5 × 100 mL). The N-terminal Fmoc group was deprotected by 
using piperidine (20 % v/v in DMF) to yield 12. Resin 12 was finally washed with 
DMF (5 × 150 mL). A small amount of the resin was cleaved using reagent R 
(TFA/thioanisole/1,2-ethanedithiol/anisole, 90:5:3:2 v/v/v/v, 2 mL) and precipitated 
with cold diethyl ether (200 mL) and finally centrifuged at 4000 rpm for 5 min. The 
residue was dissolved in water and the formation of product 12 was confirmed with 
SELDI-TOF mass spectrometer. MS (SELDI-TOF) (m/z): C56H110N28O11, calcd, 
1351.7; found, 1352.0 [M + H]
+
. 
 
General Procedure for the Synthesis of Polyarginine-1,12-Dodecanedicarboxylate  
Acylated Nucleoside Analogues (13-15). N4-4,4′-Dimethoxytrityl (DMTr)-3TC (8) 
and N4-DMTr-FTC (9) were synthesized as described in the previously published 
procedure (Agarwal et al., 2012). Peptidyl polyarginine dodecandicarboxylate resin 12 
(0.7 g), the nucleoside analogues (1, 8, or 9,  1.1 mmol), HBTU (0.417 mg, 1.1 mmol), 
and HOAt (148 mg, 1.1 mmol) were dissolved in anhydrous DMF (25 mL) in a round 
bottom flask (100 mL) followed by the addition of DIPEA (1.95 mmol, 342 µL) and 
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DIC (2.5 mmol, 383 µL) (Scheme 2). The reaction vessels were flushed with N2 and 
placed on a shaker at 4000 rpm to mix the reagents.  
 The reaction mixture was filtered off, and the resin was washed with DMF (3 × 
20 mL), methanol (3 × 20 mL), and dichloromethane (DCM, 3 × 20 mL). The resin 
was cleaved along with deprotection of Pbf and DMTr protective groups from the side 
chain of arginine by and corresponding nucleosides, respectively, using reagent R (20 
mL) for 4 h at room temperature. The resin was filtered, and the filtrate was added 
drop wise to cold diethyl ether (50 mL) for precipitation followed by centrifugation at 
4000 rpm. The precipitates were washed with diethyl ether (2 × 50 mL) to afford solid 
crude peptide-nucleoside conjugates (13-15). The precipitates were dried and 
dissolved in 50% acetonitrile and water. The conjugates were purified by preparative 
reverse-phase HPLC (Shimadzu LC-8A preparative liquid chromatograph) on a 
Phenomenex-Gemini C18 column (10 µm, 250 × 21.2 mm) at 10.0 mL/min flow rate 
using a gradient of 10% acetonitrile (0.1% TFA) in water (0.1% TFA) to 100% 
acetonitrile (0.1% TFA) (Table 2.1). Chromatograms were recorded at 220 and 265 
nm using a UV detector. The purity of final products (>95%) was confirmed by 
analytical HPLC. The chemical structures of compounds were determined by a 
SELDI-TOF mass spectrometer on a Ciphergen protein chip instrument using α-
cyano-4-hydroxycinnamic as a matrix and by 
1
H and 
13
C NMR. 
 
1-[5′-O-(3′-Fluoro-2′,3′-dideoxythymidinyl)]tetradecan-1,14-dioate conjugate of 
PolyArg (FLT-OCO(CH2)12CONH-RRRRRRR-OH, 13). Yield (210 mg, 60.5%). 
1
H NMR (400 MHz, CD3OD, δ ppm): 7.30 (s, 1H, H-6), 6.12 (dd, J = 5.7 and 8.6 Hz, 
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1H, H-1′), 5.15 (dd, J = 4.3 and 53.2 Hz, 1H, H-3′), 4.04-4.26 (m, 7H, -NH-CH-CO), 
3.90-4.00 (m, 1H, H-4′), 3.52-3.66 (m, 2H, H-5′ and H-5′′), 3.26-3.35 (m, 2H, =NH-
CH2), 2.95-3.10 (m, 10H, =NH-CH2), 2.70-2.90 (m, 2H, =NH-CH2), 2.40-2.55 (m, 
1H, H-2′′), 2.05-2.25 (m, 5H, CH2O and H-2′), 1.84-1.90 (br s, 7H, 5-CH3 and 
CH2CH2CO), 1.35-1.80 (m, 32H, =NH-CH2-CH2), 1.08-1.20 (br s, 16H, methylene 
protons). 
13
C NMR (CD3CN, 100 MHz, δ ppm): 175.87, 173.26, 172.79, 172.69, 
156.36, 135.79, 118.26, 114.78, 84.89, 82.22, 63.19, 52.82, 51.83, 48.74, 40.22, 37.14, 
33.16, 27.49, 24.07, 19.98, 19.25, 13.83, 11.43, 0.73, 0.52, 0.31, 0.11, 0.10, 0.36.MS 
(SELDI-TOF) (m/z): C66H121FN30O14, calcd, 1576.97; found, 1577.5 [M + H]
+
. 
 
1-[(−)-2′,3′-Dideoxy-3′-thiacytidine]tetradecan-1,14-dioate conjugate of PolyArg 
(3TC-OCO(CH2)12CONH-RRRRRRR-OH, 14). Yield (180 mg, 52.3%). 
1
H NMR 
(400 MHz, CD3OD, δ ppm): 8.27 (d, J = 7.8 Hz, 1H, H-6), 6.42-6.48 (m, 1H, H-1′), 
6.34 (d, J = 7.5 Hz, 1H, H-5), 5.60-5.80 (m, 1H, H-4′), 4.58-4.68 (m, 1H, -NH-CH-
CO), 4.40-4.50 (br s, 5H, -NH-CH-CO), 4.30-4.40 (m 1H, -NH-CH-CO), 3.78 (dd, J = 
12.8 and 5.4 Hz, 1H, H-5″), 3.61 (d, J = 12.8 Hz, 1H, H-5′), 3.42-3.52 (m, 1H, H-2″), 
3.22-3.40 (br s, 15H, H-2′, =NH-CH2), 2.52-5.64 (m, 2H, CH2CONH-), 2.36-2.44 (m, 
2H, CH2COO), 1.65-2.10 (m, 32H, =NH-CH2-CH2), 1.30−1.50 (br s, 16H, methylene 
protons). 
13
C NMR (CD3CN, 100 MHz, δ ppm): 176.50, 176.46, 174.91, 173.47, 
172.76, 172.69, 172.65, 172.59, 172.48, 162.08, 161.74, 159.40, 156.29, 148.20, 
143.62, 94.00, 86.78, 84.18, 63.21, 53.17, 52.83, 52.77, 52.43, 40.17, 36.95, 35.03, 
33.33, 28.51, 28.38, 28.30, 28.11, 28.02, 27.91, 27.67, 27.57, 24.96, 24.21, 24.07, 
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24.01, 23.92. MS (SELDI-TOF) (m/z): C64H119N31O13S, calcd, 1561.93; found, 1562.7 
[M + H]
+
. 
 
1-[(−)-2′,3′-dideoxy-5-fluoro-3′-thiacytidine]tetradecan-1,14-dioate conjugate of 
PolyArg (FTC-OCO(CH2)12CONH-RRRRRRR-OH, 15). Yield (130 mg, 37.5%); 
1
H NMR (400 MHz, CD3OD,  ppm): 8.11 (d, J = 6.7 Hz, 1H, H-6), 6.22-6.27 (m, 
1H, H-1'), 5.44 (dd, J = 2.9 and 4.3 Hz, 1H, H-4'), 4.68 (dd, J = 12.6 and 4.4 Hz, 1H, 
H-5''), 4.30-4.48 (m, 7H, H-5', -NH-CH-CO), 4.20-4.30 (m, 1H, -NH-CH-CO), 3.45-
4.65 (m, 1H, H-2''), 3.15-3.28 (m, 15H, H-2', CH2NH), 2.13-2.38 (m, 4H, CH2COO 
and CH2CONH), 1.40-1.90 (m, 32H, methylene protons), 1.10-1.30 (br s, 16H, 
methylene proton); 
13
C NMR (CD3CN, 100 MHz, δ ppm): 172.88, 172.41, 171.79, 
171.21, 159.47, 158.84, 158.52, 156.76, 124.80, 99.43, 86.63, 82.02, 63.77, 52.02, 
40.04, 39.83, 39.62, 39.41, 39.20, 38.99, 38.78, 36.06, 35.05, 33.16, 28.87, 28.79, 
28.35, 28.26.25.15, 24.86, 24.29. MS (MALDI-TOF) (m/z): C64H118FN31O13S, calcd, 
1580.91; found, 1581.5 [M + H]
+
. 
 
Stability and Degradation Studies. The stability of 13 was evaluated by using 
HPLC. All degradation studies were carried out at a drug concentration of 1 mg/mL. 
The solution stability studies were conducted by using the stock solution of compound 
13 in the presence of room temperature (25 C), heat (40 C), neutral (water), acidic 
(1N HCl), alkaline (1N NaOH) and oxidation (3% H2O2) conditions at 40 C. The 
compound was incubated in the above solutions for 24 hours. All the samples were 
kept at room temperature for 1h and the analytical HPLC was run for 35 min. The 
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solvent system used was water:acetonitrile (0.1% trifluoroacetic acid) and the HPLC 
was run at a flow rate of 1 mL/min at 220 nm and 256 nm wavelengths (Table 2.2).  
 
Table 2.2. HPLC method used for Stability and Degradation Studies. 
Time 
(min) 
Water 
Concentration 
A (%) 
Acetonitrile 
Concentration 
B (%) 
Flow rate 
(mL/min) 
0.00 100.0 0.0 1.0 
1.00 
20.0 
100.0 
0.0 
0.0 
100.0 
1.0 
1.0 
25.0 0.0 100.0 1.0 
30.0 100.0 0.0 1.0 
35.0 100.0 0.0 1.0 
 
  
2.3.3. Partition Coefficient (Log P). Log P HPLC studies were carried out by 
distributing 21.9 mg of compound 13 in 250 µL each of n-octanol (organic) and pH 4 
acetate buffer (aqueous). The mixture was stirred for 2 days at room temperature. The 
analytical HPLC was run using water:acetonitrile (0.1% TFA) as a solvent system at a 
flow rate of 1 mL/min at 220 nm and 256 nm wavelengths for each collected fraction 
(Table 2.2). 
 
2.3.4. Gel Formulations. Vaginal gel formulations of compound 13 were 
manufactured using non-ionic (HPC-SL) and anionic (Carbopol) polymers with and 
without the inclusion of thermo-reversible gelling (Pluronic F-127) polymer. The 
HPC-SL formulation consisted of 2.25% w/v in water while Carbopol consisted of 
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0.2% w/v. For thermogelling formulations, the aforementioned HPC-SL and Carbopol 
gels were mixed with a 20% solution of Pluronic F-127 (3:1 v/v ratio). A drug load 
comprising 1.6% (w/v) of FLT conjugate was loaded in the gels and was sealed in 
SpectraPor dialysis tubing with MWCO of 3500 Da. The tubes were suspended in 70 
ml of dissolution media (Table 2.3) held at 37 ± 0.5 °C with a stirring speed of 75 rpm 
using a 0.5 inch stir bar. The dissolution media consisted of a simulated vaginal fluid 
(Table 2.3). These dissolution samples were transferred to UV 96 well plates 
(Costar®,) and were then analyzed using a SpectraMax M2 UV detector (Molecular 
Devices, PA, USA).  
 
Table 2.3. Dissolution media composition for (6 liters) 
Chemicals Acetic 
acid 
Urea Glucose Lactic 
acid 
Glycerol Potassium 
hydroxide 
Calcium 
hydroxide 
Sodium 
chloride 
pH 
Weight 
(grams) 
6 24 30 12 0.96 8.4 1.3 21 4.2 
 
2.3.5. Anti-HIV Assays. The anti-HIV activity of the compounds was evaluated 
according to the previously reported procedure (Agarwal et al, 2010, 2011, 
Ahmadibeni, 2011, and Krebs, 2005). Compound anti-HIV activity was evaluated in 
single-round (MAGI) infection assays using X4 (IIIB) and R5 (BaL) HIV-1 and P4R5 
cells expressing CD4 and coreceptors. In summary, P4R5MAGI cells were cultured at 
a density of 1.2 × 10
4
 cells/well in a 96 well plate approximately 18 h prior to 
infection. Cells were incubated for 2 h at 37 ºC with purified, cell-free HIV-1 
laboratory strains IIIB or BaL (Advanced Biotechnologies, Inc., Columbia, MD) in the 
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absence or presence of each agent. After 2 h, cells were washed, cultured for an 
additional 46 h, and subsequently assayed for HIV-1 infection using the Galacto-Star 
-Galactosidase Reporter Gene Assay System for Mammalian Cells (Applied 
Biosystems, Bedford, MA). Reductions in infection were calculated as a percentage 
relative to the level of infection in the absence of agents, and 50% inhibitory 
concentrations (EC50) were derived from regression analysis. Each compound 
concentration was tested in triplicate wells. Cell toxicity was evaluated using the same 
experimental design but without the addition of virus. The impact of compounds on 
cell viability was assessed using an MTT (reduction of tetrazolium salts) assay 
(Invitrogen, Carlsbad, CA). 
 
2.4. Results and Discussion 
2.4.1. Chemistry 
 FLT (1), N4-amino protected 3TC (8), N4-amino protected FTC (9), and 1,12-
dodecandicarboxylate-polyargine resin were used as the building blocks. N4-DMTr-
3TC (8) and N4-DMTr-FTC (9) were synthesized according to the previously reported 
procedure (Agarwal, 2012). First, tert-butyldimethylsilyl chloride (TBDMS–Cl) was 
reacted with 3TC (2) or FTC (3) in the presence of imidazole to afford 5-O-TBDMS-
3TC (4) or 5-O-TBDMS-FTC (5). Next, the N4–amino group of 4 and 5 was 
protected with 4,4′-dimethoxytrityl (DMTr) protecting group, by reaction with DMTr-
Cl in the presence of pyridine to yield 6 and 7, respectively. Finally, TBDMS was 
removed by using tetrabutylammonium fluoride (TBAF) to yield N4-DMTr-3TC (8) 
and N4-DMTr-FTC (9) (Scheme 1).  
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Scheme 2.1.  Synthesis of N4-DMTr protected of FTC and 3TC nucleosides 
(Agarwal, 2012). 
 
 Second, the polyarginine peptide (R7) was manually synthesized by agitation 
of resin using nitrogen gas by using solid-phase Fmoc/tBu strategy. The preloaded 
Fmoc-L-arginine(Pbf) Wang resin (10) was swelled in DMF followed by deprotection 
of Fmoc group by using 20% piperidine in DMF. The resin was washed with DMF 
and coupled with Fmoc-Arg(Pbf)-OH in the presence of coupling reagents 1,1,3,3-
tetramethyluronium hexafluorophosphate (HBTU) and N,N-diisopropylethylamine 
(DIPEA) as a base, respectively, in DMF at room temperature under nitrogen. The 
deprotection and coupling cycles were repeated 5 more times followed by the final N-
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terminal Fmoc deprotection using 20% piperidine in DMF to yield NH2-polyarginine 
Wang resin 11. A small amount of resin cleavage confirmed the assembly of 
polyarginine peptide on Wang resin.  1.12-Dodecane dicarboxylic acid was coupled to 
NH2-polyarginine Wang resin 11 to yield 1,12-dodecanedicarboxylate-polyargine 
resin 12 in the presence of combination of coupling reagents (HBTU, HOAt and DIC) 
(Scheme 2.2).  
 The conjugation reaction between FLT (1) and N4-DMTr protected of 3TC 
and FTC nucleosides (8 and 9) and the resin-bound R7-dodecanoate (12) was then 
carried out through conjugation of 5-OH of nucleoside and free carboxylic acid of 
1,12-dodecanedicarboxylate-polyarginine peptidyl resin in the presence of 
combination of coupling reagents. The nucleoside conjugated compounds were then 
cleaved and deprotected by using reagent R to yield the final products (13-15) 
(Scheme 2.2). 
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Scheme 2.2. Synthesis of hepta-L-arginyl-1,12-dodecanedicarboxylate-nucleoside 
conjugates 13-15. 
 
2.4.2. Biological Evaluation  
The anti-HIV activity of the compounds was evaluated according to the 
previously reported procedure (Agarwal et al, 2010, 2011, Ahmadibeni, 2011, and 
Krebs, 2005). Table 2.4 shows the anti-HIV activities of the conjugates compared to 
their parent analogues. No cellular cytotoxicity was observed up to the highest tested 
concentration for the conjugates (EC50 > 30 M). The conjugates showed no 
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significant anti-HIV activity against cell associated virus (EC50>30 M). All 
conjugates exhibited less anti-HIV activity when compared with the parent nucleoside 
analogues against cell free virus. FLT conjugate 13 (EC50 = 2.9-3.1 M) showed less 
potency than its parent nucleoside (EC50 = 0.1-0.2 M) against X4 and R5 cell free 
virus. FTC conjugate 15 (EC50 = 1.5-3.0 M) showed less anti-HIV-1 activity when 
compared to that of FTC (EC50 = 0.18-0.48 M) against X4 and R5 cell free virus. 
3TC conjugate 14 showed approximately 2-fold higher inhibition against X4 virus 
(EC50 = 8.7 M) than the R5 virus strain (EC50=16.6 M) but exhibited also less 
potency than that of 3TC (EC50 = 2.6-7.5 M). The conjugates were less potent than 
their parent structures possibly due to the limited uptake. Different strains of HIV are 
known to have different gp120 V3 loops. Both X4 and R5 strains of HIV possess a 
high positive charge density on their V3 loop (Meylan et al., 1994; Maulard et al, 
2000), suggesting that the presence of positive charge on the conjugates could block 
the interaction with gp120. 
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Table 2.4. Anti-HIV activity of hepta-L-arginyl-1,12-dodecanedicarboxylate-
nucleoside conjugates.  
Compound Chemical Name  
Cytotoxicity Cell- Free Virus Cell-
Associated 
Virus 
    CTSa 
EC50
b(M) 
X4c  
EC50 (M) 
R5d  
EC50 (M) 
CTCe  
EC50 (M) 
      
FLT (1) 3'-Fluoro-2',3'-deoxythymidine    >100 0.2 0.1     >100 
3TC (2) (-)-2',3'-Dideoxy-3'-thiacytidine    >100 7.5 2.6     18.4 
FTC (3) (-) 2',3'–Dideoxy-5-fluoro-3'-thiacytidine     >100   0.48 0.18     21.9 
13 FLT-CO-(CH2)12-CO-R7     >30 2.9 3.1     >30  
14 3TC-CO-(CH2)12-CO-R7     >30 8.7 16.6     >30 
15 FTC-CO-(CH2)12-CO-R7     >30 3.0 1.5    >30 
      
aCytotoxicity assay (MTS); b50% Effective concentration; cSingle-round infection assay 
(lymphocytotropic strain, X4); dSingle-round infection assay (monocytotropic strain, R5); eCell-
associated transmission assay (X4). 
 
2.4.3. Forced Degradation, Log P Determination, and Gel formulation of FLT 
conjugate.  These conjugates were designed to be used in areas where shipping and 
storage conditions are not ideal in terms of temperature and humidity. Thus, it was 
necessary to determine the relative stability of these compounds under different 
conditions. Compound 13 was selected for further evaluation in solution state 
degradation studies and determination of lipid solubility (partition coefficient). Since 
FLT-conjugate contain several potentially labile bonds, forced degradation of an 
aqueous solution of 13 at elevated temperature, in acid, base, and under oxidizing 
conditions, were conducted.  
At heated (panel B) conditions, significant degradation of the compound 13 was 
observed resulting in a second HPLC peak at 9 min. Under both acidic and alkaline 
conditions, the compound degraded to a great extent resulting in a different peak at 7 
min (panels C and D). Minimal degradation of the drug was noted at neutral (panel E) 
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and oxidative (H2O2) (panel F) conditions. (Figure 2.2). Thus, the FLT conjugate was 
relatively stable in neutral and oxidative conditions, but less stable in heated, acidic, 
and alkaline conditions. 
 
A
B
C
D
E
F
 
 
Figure 2.2. Degradation Studies of FLT conjugate 13. A: Standard 13, Retention 
time 9.7 min; B: Heat: 1 mL stock + 1 mL methanol at  40 °C; C: Acid: 1 mL 
stock + 1 mL 1N HCl at 40°C; D: Base: 1 mL stock + 1 mL 1N NaOH at 40 °C; 
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E: Oxidation: 1 mL stock + 1 mL H2O2 at 40 °C; F: Water: 1 mL stock + 1 mL 
H2O at 40 °C. 
 
 
 
The Log P of the compound was determined by distributing the compound 
between equal volume of n-octanol (organic) and pH 4 acetate buffer (aqueous) with 
stirring at room temperature for 2 days, followed by HPLC studies. The Log P of the 
compound was found to be -0.34, indicating that the compound is hydrophilic, most 
likely due to the presence of several guanidinium moieties from hepta-L-arginine. 
These data suggest that the compound is still very hydrophilic despite the presence of 
the long 1,12-dodecane dicarboxylic acid linker. 
Various gel formulations of the compound were manufactured using non-ionic 
(HPC-SL) and anionic (Carbopol) polymers with and without the inclusion of the 
thermo-reversible gelling (Pluronic F-127) polymer. The derivative was used for 
dissolution studies using four different gels with and without the thermogelling 
polymer. The HPC-SL formulation consisted of 2.25% w/v in water while Carbopol 
consisted of 0.2% w/v. For the thermogelling formulations, the HPC-SL and Carbopol 
gels were mixed with 20% w/v solution of Pluronic F-127(3:1 v/v ratio) in water. The 
formulations were then sealed in dialysis tubes and the rate and extent of compound 
dissolution were determined in simulated vaginal fluid at 37°C. There was no 
observed drug release that could be identified by UV spectrophotometry at 220 nm 
and 256 nm, suggesting that the compound was either unstable in these formulations. 
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2.5. Conclusions 
  Three poly-L-arginyl-1,12-dodecanedicarboxylate nucleoside conjugates of 
FLT, 3TC, and FTC were designed and synthesized using solid-phase chemistry. The 
structures of the compounds were confirmed by NMR and mass spectroscopy. The 
compounds were evaluated for their anti-HIV activity against cell-free and cell-
associated virus. FLT conjugate 13 showed EC50 values of 2.9-3.1 M against X4 and 
R5 virus. The compound was relatively stable in neutral and oxidative conditions, and 
unstable in heated, acidic, and alkaline conditions. FLT conjugate was hydrophilic as 
the Log P was found to be -0.34. The compound was unstable or did not undergo 
release from the tested hydrogel formulations. These data indicate that the presence of 
positively-charged CPP could impede the interactions between positively charged V3 
loop in gp120 and the conjugates. Further optimization of conjugated CPP-fatty acid-
nucleoside conjugates is required to generate compounds with improved anti-HIV 
activity and optimized stability and formulation performance.  
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